一般演題（口演）45 ALK・ROS1融合遺伝子陽性肺癌

[O45-2] Real-world Treatment Patterns and Subsequent Treatment Efficacy After 1L Brigatinib from ALTA-1L

Angelo Delmonte¹, ^○Myung-Ju Ahn², Sharmistha Ghosh³, Maximilian Hochmair^4,5, Tsung-Ying Yang⁶, James Chih-Hsin Yang⁷, Ji-Youn Han⁸, Karin Holmskov Hansen⁹, Yanyu Wu¹⁰, Yin Wan¹⁰, Huamao Mark Lin¹⁰, Julian Kretz¹¹, Bradley Hupf¹⁰, Ahmet Melih Kurec¹², Eric N. Churchill¹³, Robert J. Fram¹⁰, Citadel Jungco Cabasag¹⁴, Vishal Goriya¹⁵, Yuzhe Zhao¹⁶, Maria Rosario Garcia Campelo¹⁷ (1.IRCCS Istituto Romagnolo per lo Studio dei Tumori - “Dino Amadori”（IRST）, Meldola, Forli - Cesena, Italy, 2.Division of Hematology, Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, 3.Guy's and St. Thomas' NHS Foundation Trust, London, England, United Kingdom, 4.Department of Respiratory and Critical Care Medicine, Klinik Floridsdorf, Vienna, Austria, 5.Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Vienna, Austria, 6.Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, 7.National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan, 8.National Cancer Center, Goyang, Republic of Korea, 9.Odense University Hospital, Odense C. Denmark., 10.Takeda Development Center Americas, Inc., Cambridge, MA, USA, 11.Takeda Pharmaceuticals International AG, Glattpark-Opfikon（Zurich）, Switzerland, 12.Takeda Pharmaceutical International Singapore Emerging Markets, Singapore, 13.Takeda Pharmaceuticals U.S.A. Inc., Lexington, MA, USA, 14.IQVIA RDS France, Courbevoie, France, 15.IQVIA RDS（India）Pvt Ltd, Thane Maharashtra, India, 16.IQVIA RDS（Shanghai）Co., Ltd., Shanghai, China, 17.Medical Oncology Department, University Hospital A Coruña, and Biomedical Research Institute（INIBIC, A Coruña）, A Coruña, Spain)

アンコール演題